Viveve Medical, Inc.

Moat Score
Safety Score

Market Cap $1.06K
PE -0
Debt $5.63M
Cash $5.91M
EV -$277.94K
FCF -$16.83M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$28.14M
EBIT	-$21.15M
ROE	-2K%
ROA	-174%
FCF	-$16.83M
Equity	$1.18M
Growth Stability	1
PE	-0
PB	0
P/FCF	-0
P/S	0
Price/Cash	5.55K
Debt/Equity	4.75
Debt/FCF	-0.33
Net Margins	-402%
Gross Margins	16%
Op. Margins	-310%
Sales Growth YoY	4%
Sales Growth QoQ	-6%
Sales CAGR	1%
Equity CAGR	9%
Earnings Growth YoY	-10%

Earnings Growth QoQ	-11%
Sales CAGR 5Y	-24%
Equity CAGR 5Y	-11%
Earnings CAGR 3Y	12%
Sales CAGR 3Y	12%
Equity CAGR 3Y	-36%
Market Cap	$1.06K
Revenue	$6.83M
Assets	$12.15M
Total Debt	$5.63M
Cash	$5.91M
Shares Outstanding	10.64M
EV	-277.94K
Moat Score	0%
Safety Score	50%
Working Capital	-1.23M
Current Ratio	0.89
Gross Profit	$1.12M
Shares Growth 3y	23%
Equity Growth QoQ	-78%
Equity Growth YoY	-94%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

No description available

SEC Filings

Direct access to Viveve Medical, Inc. (VIVE) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2022
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2021
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2020
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Viveve Medical, Inc. compare to its competitors?

Not enough data to generate a comparison chart between Viveve Medical, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Viveve Medical, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Viveve Medical, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Viveve Medical, Inc..

Years

Calculation mode

= -$168M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$17M	-$17M	-$17M	-$17M	-$17M	-$17M	-$17M	-$17M	-$17M	-$17M	-$17M	-$168M
DCF		-$15M	-$14M	-$13M	-$11M	-$10M	-$9.5M	-$8.6M	-$7.8M	-$7.1M	-$6.5M	-$65M
Value	-$168M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	TTM
Net Margins	-7K%	-859%	-282%	-242%	-270%	-653%	-476%	-416%	-402%
ROA	-	-104%	-129%	-93%	-96%	-114%	-111%	-80%	-174%
ROE	-	-316%	5K%	1K%	-1K%	-260%	-374%	-177%	-2K%

Bad Net Margins (-401.93%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	TTM
Debt over FCF	-	-0.82	-0.65	-1.41	-1.06	-0.19	-0.03	-0	-0.33
Debt over Equity	-6.27	2.55	-29.3	-19.44	9.75	0.36	0.06	0	4.75
Growth Stability	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0.33)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Bad Debt/Equity ratio (4.75)

The company is overleveraged and has a bad balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	CAGR 5Y
Revenue YoY growth	-	2K%	394%	114%	21%	-65%	-17%	17%	-24%
Earnings YoY growth	-	101%	62%	84%	35%	-14%	-39%	3%	-
Equity YoY growth	-	-568%	-110%	542%	-289%	236%	-58%	116%	-11%
FCF YoY growth	-	101%	49%	95%	26%	-29%	-50%	-17%	-